Rock Creek Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Rock Creek Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-44	Closed	-$11K	–	187
2022 Q1	$11K	Sell	44 -3,264	-99%	-$775K	﹤0.01%	159
2021 Q4	$803K	Buy	+3,308	New	+$643K	0.12%	67
2021 Q3	–	Sell	-10	Closed	-$2K	–	195
2021 Q2	$2K	Buy	+10	New	+$2.09K	﹤0.01%	180
2020 Q4	–	Sell	-298	Closed	-$81K	–	204
2020 Q3	$81K	Sell	298 -143	-32%	-$39.5K	0.04%	169
2020 Q2	$128K	Buy	+441	New	+$120K	0.07%	158

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Rock Creek Group's VRTX Position: Q2 2022 in Review

Rock Creek Group sold out of Vertex Pharmaceuticals (VRTX) in Q2 2022, closing a stake of 44 shares — an estimated $11K sold.

Rock Creek Group first reported a position in VRTX in Q2 2020 and held it in 5 quarters. The position peaked at $803K in Q4 2021. 1,106 funds tracked by Wall St. Rank hold VRTX as of Q2 2022.

Rock Creek Group reported no remaining Vertex Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Rock Creek Group sold 44 Vertex Pharmaceuticals shares in Q2 2022, an estimated $11K.
Rock Creek Group first reported a position in Vertex Pharmaceuticals in Q2 2020 and held it in 5 quarters.
Rock Creek Group's Vertex Pharmaceuticals position peaked at $803K in Q4 2021.
1,106 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2022.

Based on Rock Creek Group's 13F filing for Q2 2022, filed 8 Aug 2022.